Anavex Life Sciences Corp - Company Profile
Powered by 
All the data and insights you need on Anavex Life Sciences Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Anavex Life Sciences Corp Strategy Report
- Understand Anavex Life Sciences Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Anavex Life Sciences Corp patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4003326A4 | Search Report | ANAVEX2-73 ZUR BEHANDLUNG VON GENETISCHEN NEUROENTWICKLUNGSSTÖRUNGEN | A61K31/341; A61K47/10; A61K47/12; A61K47/26; A61K47/36; A61K9/0053; A61K9/0095; A61P25/00; A61P25/28 | August 24, 2022 |
| EP3407880B1 | Grant | BEHANDLUNG DES RETT SYNDROMS MIT DER VERBINDUNG A2-73 | A61K31/341; A61P25/00 | August 17, 2022 |
| US20220249427A1 | Application | ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS | A61K31/341; A61P25/28 | August 11, 2022 |
| US20220226278A1 | Application | OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT | A61K31/13; A61K31/135; A61K31/15; A61K31/27; A61K31/341; A61K31/4045; A61K31/438; A61K31/439; A61K31/445; A61K31/485; A61K31/495; A61K31/5375; A61K31/55; A61P25/28 | July 21, 2022 |
| EP4003326A1 | Application | ANAVEX2-73 ZUR BEHANDLUNG VON GENETISCHEN NEUROENTWICKLUNGSSTÖRUNGEN | A61K31/341; A61K47/10; A61K47/12; A61K47/26; A61K47/36; A61K9/0053; A61K9/0095; A61P25/00; A61P25/28 | June 01, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer